Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Buy
65
ATAI Quote, Financials, Valuation and Earnings
Last price:
$2.50
Seasonality move
:
-5.34%
Day range:
$2.18 - $2.33
52-week range:
$1.03 - $2.57
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
203.97x
P/B ratio:
3.04x
Volume:
1.7M
Avg. volume:
2M
1-year change:
37.5%
Market cap:
$462.8M
Revenue:
$308K
EPS (TTM):
-$0.91
Analysts' Opinion
-
Consensus RatingATAI Life Sciences NV has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.00, ATAI Life Sciences NV has an estimated upside of 246.32% from its current price of $2.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $2.31.
Fair Value
-
According to the consensus of 5 analysts, ATAI Life Sciences NV has 246.32% upside to fair value with a price target of $8.00 per share.
ATAI vs. S&P 500
-
Over the past 5 trading days, ATAI Life Sciences NV has overperformed the S&P 500 by 12.25% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ATAI Life Sciences NV does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ATAI Life Sciences NV revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter ATAI Life Sciences NV reported revenues of $1.6M.
Earnings Growth
-
ATAI Life Sciences NV has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ATAI Life Sciences NV reported earnings per share of -$0.15.
Enterprise value:
388.6M
EV / Invested capital:
2.21x
Price / LTM sales:
203.97x
EV / EBIT:
--
EV / Revenue:
208.58x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-4.98x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-71.8%
Net Income Margin (TTM):
-7997.16%
Return On Equity:
-92.32%
Return On Invested Capital:
-81.4%
Operating Margin:
-1308.17%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $269K | -- | $1.9M | -- | $1.6M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$144.2M | -$113.7M | -$98.6M | -$23.9M | -$20.3M | |
| EBITDA | -$134.7M | -$28.8M | -$145.1M | -$24.9M | -$25.2M | |
| Diluted EPS | -$0.95 | -$0.24 | -$0.91 | -$0.17 | -$0.15 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $131.1M | $348.8M | $267.9M | $117.5M | $116M | |
| Total Assets | $145.3M | $383.7M | $280.7M | $269.1M | $195.8M | |
| Current Liabilities | $19.1M | $22.1M | $20M | $15M | $28.5M | |
| Total Liabilities | $25.3M | $29.4M | $40.1M | $45.9M | $43.5M | |
| Total Equity | $120M | $354.4M | $240.6M | $223.3M | $152.3M | |
| Total Debt | $3M | $725K | $15.2M | $19.7M | $23.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$101.6M | -$85.6M | -$77.7M | -$22.6M | -$17.8M | |
| Cash From Investing | $143.9M | -$57.8M | $36.7M | $11.5M | -$11M | |
| Cash From Financing | $20.9M | -$8.6M | $65M | -- | $59.6M | |
| Free Cash Flow | -$103M | -$85.7M | -$78.1M | -$22.6M | -$18.1M | |
ATAI
Sector
Market Cap
$462.8M
$33.4M
Price % of 52-Week High
90.06%
45.16%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
37.5%
-40%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.15
200-day SMA
Buy
Level
$1.47
Bollinger Bands (100)
Buy
Level
1.31 - 1.95
Chaikin Money Flow
Sell
Level
-12.5M
20-day SMA
Buy
Level
$1.76
Relative Strength Index (RSI14)
Buy
Level
76.68
ADX Line
Buy
Level
35.1
Williams %R
Sell
Level
-6.9559
50-day SMA
Buy
Level
$1.55
MACD (12, 26)
Buy
Level
0.22
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
37.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.6118)
Sell
CA Score
(Annual)
Level (-2.0111)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (7.0467)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Stock Forecast FAQ
In the current month, ATAI has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ATAI average analyst price target in the past 3 months is $8.00.
-
Where Will ATAI Life Sciences NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that ATAI Life Sciences NV share price will rise to $8.00 per share over the next 12 months.
-
What Do Analysts Say About ATAI Life Sciences NV?
Analysts are divided on their view about ATAI Life Sciences NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ATAI Life Sciences NV is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is ATAI Life Sciences NV's Price Target?
The price target for ATAI Life Sciences NV over the next 1-year time period is forecast to be $8.00 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ATAI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ATAI Life Sciences NV is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ATAI?
You can purchase shares of ATAI Life Sciences NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ATAI Life Sciences NV shares.
-
What Is The ATAI Life Sciences NV Share Price Today?
ATAI Life Sciences NV was last trading at $2.50 per share. This represents the most recent stock quote for ATAI Life Sciences NV. Yesterday, ATAI Life Sciences NV closed at $2.31 per share.
-
How To Buy ATAI Life Sciences NV Stock Online?
In order to purchase ATAI Life Sciences NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for Jun 2
Regeneron Pharmaceuticals [REGN] is up 1.98% over the past day.
Buy
55
RGC alert for Jun 2
Regencell Bioscience Holdings [RGC] is down 12.18% over the past day.
Sell
42
AMBA alert for Jun 2
Ambarella [AMBA] is down 0.63% over the past day.
